Sandoz biosimilar abatacept?

Sandoz has been developing a biosimilar to abatacept (the reference product is Orencia). However, as of my last update, there isn’t a widely approved Sandoz abatacept biosimilar in major markets, and regulatory status can vary by country.

If you want, I can fetch the latest region-specific status (FDA/EMA approvals, planned launch dates, or trial results) and summarize:
- the expected trade name (if any) and regional approvals
- indications and dosing expectations
- how it compares to Orencia in efficacy and safety data
- any notes on interchangeability or payer considerations

In the meantime, here’s quick context on abatacept biosimilars:
- Abatacept is a fusion protein that inhibits T-cell activation by blocking CD28 co-stimulation.
- Approved uses include rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and axial spondyloarthritis (with some indications in children for JIA).
- Biosimilars aim to have no clinically meaningful differences from Orencia in terms of safety, purity, and potency, but regulatory agencies assess them rigorously, including immunogenicity and comparative efficacy.

Tell me your country or region and what you want to know (regulatory status, pricing, clinical data, or dosing), and I’ll pull the latest specifics.